Cargando…

Erythropoiesis-stimulating agents and cardiovascular mortality: A systematic review and meta-analysis of 17 studies and 372,156 hemodialysis patients

INTRODUCTION: Prior studies on the association between erythropoiesis-stimulating agents (ESAs) and cardiovascular mortality in hemodialysis patients have yielded conflicting findings. We aimed to clarify this relationship through a systematic review and meta-analysis of current evidence. METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karimi, Zahra, Raeisi Shahraki, Hadi, Mohammadian-Hafshejani, Abdollah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632731/ https://www.ncbi.nlm.nih.gov/pubmed/37953767 http://dx.doi.org/10.1016/j.ijcrp.2023.200220

Ejemplares similares

Investigating the relationship between erythropoiesis-stimulating agents and mortality in hemodialysis patients: A systematic review and meta-analysis
por: Karimi, Zahra, et al.
Publicado: (2023)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Yasukawa, Minoru, et al.
Publicado: (2022)

Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Lee, Yu-Ting, et al.
Publicado: (2022)

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013)

Resistance to Erythropoiesis-Stimulating Agents Is Associated with Arterial Microcalcification in Early Hemodialysis Patients
por: Won, Hye Sung, et al.
Publicado: (2014)

Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodialysis patients
por: Koike, Kiyomi, et al.
Publicado: (2016)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

The accuracy of “Preliminary estimation of the novel coronavirus disease (COVID-19) cases in Iran: A modelling analysis based on overseas cases and air travel data”
por: Ahmadi, Ali, et al.
Publicado: (2020)

Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients
por: Nguyen, Timothy V., et al.
Publicado: (2011)

The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients
por: Sibbel, Scott, et al.
Publicado: (2016)

Responsiveness to an erythropoiesis-stimulating agent is correlated with body composition in patients undergoing chronic hemodialysis
por: Lee, Hyang Yun, et al.
Publicado: (2022)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

Serum trace metal association with response to erythropoiesis stimulating agents in incident and prevalent hemodialysis patients
por: Brier, Michael E., et al.
Publicado: (2020)

Erythropoiesis stimulating agents are associated with serum fibroblast growth factor 23 metabolism in patients on hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2020)

Comparison of Patient Survival According to Erythropoiesis-Stimulating Agent Type of Treatment in Maintenance Hemodialysis Patients
por: Kang, Seok Hui, et al.
Publicado: (2023)

Association of the erythropoiesis-stimulating agent resistance index and the geriatric nutritional risk index with cardiovascular mortality in maintenance hemodialysis patients
por: Yajima, Takahiro, et al.
Publicado: (2021)

Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents
por: van der Weerd, Neelke C., et al.
Publicado: (2012)

The Resection of Thyroid Cancer Was Associated with the Resolution of Hyporesponsiveness to an Erythropoiesis-stimulating Agent in a Hemodialysis Patient with Aceruloplasminemia
por: Nagata, Soichiro, et al.
Publicado: (2017)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

The Relationship between Statins and Survival of Colorectal Cancer
por: Mohammadian, Mahdi, et al.
Publicado: (2023)

Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome
por: Bernieh, Bassam, et al.
Publicado: (2014)

Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients
por: Rivara, Matthew B., et al.
Publicado: (2015)

Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial
por: Saglimbene, Valeria, et al.
Publicado: (2017)

Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis
por: Kobayashi, Shizuka, et al.
Publicado: (2022)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
por: Fishbane, Steven, et al.
Publicado: (2020)

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients
por: Gupta, Ajay, et al.
Publicado: (2015)

Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma
por: Horváth-Puhó, Erzsébet, et al.
Publicado: (2018)

Some Facts on Incidence and Mortality of Cancer in Iran
por: MOHAMMADIAN, Mahdi, et al.
Publicado: (2017)

Selenium Removal from Water and Wastewater by Different Technologies: A Systematic Review
por: Fadaei, Abdolmajid, et al.
Publicado: (2023)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
por: Melosky, B.L.
Publicado: (2008)

Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents
por: Yan, X, et al.
Publicado: (2013)

Erythropoiesis stimulating agents and reno-protection: a meta-analysis
por: Elliott, Steve, et al.
Publicado: (2017)

Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
por: Wish, Jay B.
Publicado: (2020)

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k25ueocbp001p4qh360dq406p7